{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:31Z","timestamp":1790887771049,"version":"4.1.0"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2025,3,31]]},"abstract":"<jats:p>&lt;sec&gt;&lt;title&gt;BACKGROUND&lt;\/title&gt;To evaluate currently recommended dosage using the population pharmacokinetics (PK) of bedaquiline (BDQ), clofazimine, cycloserine, linezolid (LZD) and moxifloxacin (MFX) in patients with multidrug-resistant TB (MDR-TB) and type II\n diabetes mellitus (DM).&lt;\/sec&gt;&lt;sec&gt;&lt;title&gt;METHODS&lt;\/title&gt;A prospective multi-centre PK study was conducted in China between 2016 and 2019. Population PK models were developed using nonlinear mixed-effect analyses based on the blood samples collected by rich sampling.\n The probability of target attainment (PTA) analysis was estimated using the Monte Carlo simulation.&lt;\/sec&gt;&lt;sec&gt;&lt;title&gt;RESULTS&lt;\/title&gt;A total of 1,450 plasma samples were collected from 58 participants with DM. Simulations showed that the WHO-recommended regimens\n of LZD (600 mg daily) and MFX (400 mg daily) achieved &gt; 90% PTA for <jats:italic>M. tuberculosis<\/jats:italic> isolates with MICs below 0.50 and 0.25 mg\/L, respectively. The currently recommended BDQ regimen (400 mg daily for 2 weeks, followed by 200 mg thrice weekly) might fail to achieve &gt;90% PTA at an\n MIC of 0.06 mg\/L or higher.&lt;\/sec&gt;&lt;sec&gt;&lt;title&gt;CONCLUSION&lt;\/title&gt;The population PK models for the five second-line drugs were established in Chinese patients with MDR-TB and DM. The model-based dosage evaluation showed that dosing adjustments may be necessary\n for isolates with borderline resistance levels.&lt;\/sec&gt;<\/jats:p>","DOI":"10.5588\/ijtld.24.0481","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:32:21Z","timestamp":1743222741000},"page":"164-170","source":"Crossref","is-referenced-by-count":2,"title":["Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes"],"prefix":"10.5588","volume":"29","author":[{"given":"J.","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Guhua Hospital, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Davies Forsman","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden;, Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Ning","sequence":"additional","affiliation":[{"name":"Zigong City Centre for Disease Control and Prevention, Zigong, Sichuan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Cao","sequence":"additional","affiliation":[{"name":"Zigong City Centre for Disease Control and Prevention, Zigong, Sichuan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2025\/00000029\/00000004\/art00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:32:28Z","timestamp":1743222748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.24.0481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,31]]}},"alternative-id":["1027-3719(20250331)29:4L.164;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.24.0481","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}